O Keefe Stevens Advisory Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)

O Keefe Stevens Advisory Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 47.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 95,878 shares of the biopharmaceutical company's stock after acquiring an additional 31,010 shares during the period. Pfizer comprises about 0.8% of O Keefe Stevens Advisory Inc.'s portfolio, making the stock its 26th biggest position. O Keefe Stevens Advisory Inc.'s holdings in Pfizer were worth $2,544,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of PFE. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. Marshall Wace LLP grew its position in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock valued at $150,481,000 after buying an additional 8,378,173 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after buying an additional 6,977,587 shares during the period. International Assets Investment Management LLC bought a new position in shares of Pfizer during the third quarter worth about $146,481,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock worth $211,737,000 after acquiring an additional 4,546,809 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.7 %

PFE traded down $0.19 during trading on Friday, hitting $26.30. 35,146,711 shares of the company's stock were exchanged, compared to its average volume of 35,869,448. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market cap of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The business's 50 day moving average is $26.08 and its two-hundred day moving average is $27.99. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.17) EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio is presently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PFE shares. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.